Lv4
520 积分 2023-02-02 加入
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance
19天前
已完结
Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment
20天前
已完结
1354 Anti-CCR8 antibody CHS-114 (SRF114) depletes tumor-infiltrating regulatory T cells in dissociated tumors from patients with head and neck squamous cell carcinoma
20天前
已关闭
Preclinical and translational pharmacology of afucosylated anti‐CCR8 antibody for depletion of tumour‐infiltrating regulatory T cells
25天前
已完结
CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory
28天前
已完结
821 The potential clinical usage of Fc-optimized anti-CCR8 therapeutic antibodies as a monotherapy or combined with other promising immune-modulating agents beyond PD-1/L1
1个月前
已完结
Low expression of CD24 is associated with poor survival in colorectal cancer
1个月前
已完结
Co-expression of CD24 and Hsp70 as a prognostic biomarker for lung cancer
1个月前
已完结
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
2个月前
已完结
Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic challenges
3个月前
已完结
皖公网安备34019202002308
